Lymphoma Expert Dr. Craig Moskowitz Joins Sylvester as Physician-in-Chief for Oncology Service Line
Craig H. Moskowitz, M.D., one of the world’s leading experts on lymphoma, will join Sylvester Comprehensive Cancer Center on May 14 as Physician-in-Chief for the Oncology Service Line.
Moskowitz received his M.D. degree at Wayne State University School of Medicine. He completed an internal medicine internship and residency at Jacobi Hospital, affiliated with Albert Einstein College of Medicine, and a fellowship in hematology oncology at Memorial Sloan Kettering Cancer Center. Upon completing his fellowship, he joined the Memorial Sloan Kettering faculty in 1995. He became a Member of Memorial Sloan Kettering in 2011 and received the Steven A. Goldberg Chair in Lymphoma Research in 2014.
He concurrently has been a faculty member at Weill Medical College of Cornell University in New York City, rising to the rank of professor in 2011. He is board certified in internal medicine, medical oncology and hematology. Additionally, he is the author of more than 275 articles in high-impact journals and a sought-after speaker at scientific conferences worldwide.
“Dr. Moskowitz is an internationally recognized leader in lymphoma clinical research and treatment, specializing in the care of patients with Hodgkin lymphoma and non-Hodgkin lymphoma,” said Sylvester Director Stephen D. Nimer, M.D. “His research has been practice changing; his work has led to changes in the international standard of care for lymphoma patients.”
“I am very pleased to be joining the team at Sylvester,” said Moskowitz. “Dr. Nimer was one of my mentors early in my career, and I very much look forward to working with him again.”
Moskowitz’s twofold research focuses on improving the outcomes of patients with poor-risk diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma. One area of accomplishment has been to optimize high-dose therapy and autologous stem cell transplantation, as well as new agents, to improve “salvage” therapy for patients with disease that has returned or is not responding to standard therapy.
His second area of accomplishment has been to develop strategies that optimize the treatment of newly diagnosed DLBCL patients, according to the likelihood of their disease recurring. These include designing risk-adapted therapies, based on risk factors present before treatment and also the results of imaging studies.
As the Sylvester OSL Physician-in-Chief, Moskowitz will be responsible for the development, implementation and administration of high quality, value-based oncology care at the main campus and satellites. He will work across departments to improve our multidisciplinary care of cancer patients. In an effort to drive the standardization and improvement of patient care, Moskowitz will help create treatment guidelines to meet the organizational goals of patient safety, quality and satisfaction. With assistance from the Chief Clinical Officer and Chief Medical Officer, he will drive the implementation of clinical research trials at all Sylvester facilities.
As leader of the Site Disease Groups, whose goal is to create practice-changing clinical and translational research, Moskowitz will collaborate with group directors to enhance the patient navigation system and foster multidisciplinary participation in the development and piloting of clinical trials.
He will be a Professor in the Miller School of Medicine, within the Department of Medicine and the Division of Hematology. He will work closely with faculty leaders to mentor fellows and junior faculty members, and foster more efficient, transparent lines of communication.